-
HER2 ADC melee is coming!
Time of Update: 2021-07-19
At present, two HER2 ADC drugs have been approved for marketing globally, namely Roche’s Kadcyla (T-DM1) and AstraZeneca/Daiichi Sankyo’s Enhertu (DS-8201), the former It was approved for marketing by the FDA in 2013, and the approved indications include HER2-positive metastatic breast cancer and HER2-positive early breast cancer; the latter was approved for marketing by the FDA in December 2019, and the indication is HER2-positive breast cancer, January 2021 May extend the indications to HER2-positive stomach or gastroesophageal junction adenocarcinoma .
-
Hengrui Medicine SHR-1707 is approved for clinical trial for the treatment of Alzheimer's disease
Time of Update: 2021-07-19
On March 10, 2021, Hengrui Medicine's SHR-1707 clinical trial application was approved by NMPA for the treatment of Alzheimer's disease .
However, in recent years, many Aβ antibodies have collapsed, and Alzheimer's disease has never achieved a real breakthrough .
-
Roche acquires GenMark for US$1.8 billion
Time of Update: 2021-07-18
On March 15, Roche announced that it had reached a final merger agreement with GenMark Diagnostics to acquire its molecular test, which aims to simultaneously screen patient samples for multiple infections .
-
Deqi Pharmaceutical is included in Shenzhen-Hong Kong Stock Connect and Hong Kong Stock Connect
Time of Update: 2021-07-18
Only 4 months after listing, Deqi Pharmaceutical was selected into 9 benchmarks and thematic indexes including the Hang Seng Composite Index and included in Shenzhen-Hong Kong Stock Connect, which fully demonstrated the recognition of the company's strength and development potential by the capital market .
-
Focusing on digital business model innovation, Takeda China Innovation Incubator launched
Time of Update: 2021-07-18
Takeda China recently announced that it has officially launched an open incubation and innovation platform-Takeda China's innovation incubator TakedaSpark, to accelerate the co-creation of digital me
-
Thanks to the success of the new crown vaccine, Pfizer's CEO's annual salary exceeds 21 million U.S. dollars
Time of Update: 2021-07-18
The company's sales this year are expected to reach 15 billion US dollars, and CEO Albert Bourla received more than 21 million US dollars in salary .
Pfizer, riding high on COVID-19 vaccine launch, pays CEO Bourla $21 million for 2020 2.
-
CSPC obtains exclusive rights to anti-IL-4Rα monoclonal antibody CM310 in China
Time of Update: 2021-07-18
According to the agreement, Jinmante Biotech agreed to pay a down payment of RMB 70,000,000 to Connoa Biology and a development milestone payment of RMB 100,000,000 based on the development progress of the product in the region .
-
Big waves scouring the sand?
Time of Update: 2021-07-18
After another pharmaceutical company's salary structure adjustment plan from Jiangsu was announced, a medical representative said that the basic salary had dropped to just over 1,000 after deducting five insurances and one housing fund .
-
Deck Pharma appoints Minyoung Kim as General Manager of Deck Korea
Time of Update: 2021-07-18
As the general manager of Deqi Korea, Minyoung will be guided by the company's vision to establish a first-class professional team and actively cooperate with local health organizations to promote the commercialization of innovative products and provide new treatment options for Korean patients .
-
"The Guardian of Anti-Epilepsy" officially launched the first epilepsy popular science competition
Time of Update: 2021-07-18
This popular science competition actively responded to the call of "Healthy China 2030", mobilized and encouraged the majority of epilepsy workers to participate in popular science creation, stimulated the vitality of popular science creation, popularized knowledge about epilepsy diseases and standardized diagnosis and treatment, and called on the whole society to correctly understand epilepsy diseases and build understanding A good atmosphere of caring for patients with epilepsy will promote the development of people’s health in an all-round way .
-
Rongchang Biotech's first original innovative drug, Tai'ai®, was approved to start the "dual target" era of systemic lupus erythematosus
Time of Update: 2021-07-18
As the world's first "dual target" biological agent approved for the treatment of SLE, Tai Ai® inhibits the overexpression of two cytokines, BLyS and APRIL, and inhibits the maturation and differentiation of abnormal B cells, thereby reducing the body's own immune response.
-
Senior Vice President and CMO of Betta Pharmaceuticals resigns
Time of Update: 2021-07-18
Mao Li resigned from the position of director, senior vice president and chief medical officer of the company due to personal reasons.
Mao Li has been handed over well, and his resignation as senior vice president and chief medical officer will not affect the normal operation of the company .
-
Hengrui Medicine: The clinical trial of SHR-1707 injection was approved by the State Food and Drug Administration
Time of Update: 2021-07-18
At present, similar products of many companies are in the clinical research and development stage, and the indication is Alzheimer's disease .
Up to now, the accumulated research and development expenses of SHR-1707 related projects are approximately RMB 40.
-
Benefiting from the success of immunization drugs, AbbVie CEO's annual salary increases by 11%
Time of Update: 2021-07-18
A big question facing AbbVie's chief executive officer (CEO) Gonzalez during his tenure was whether he could lead the Illinois pharmaceutical company through the patent cliff crisis of the revenue cornerstone Humira .
-
Yiling Pharmaceutical: Lianhua Qingwen Capsules Obtained Kenyan Botanical Drug Registration Approval
Time of Update: 2021-07-18
In 2020, Lianhua Qingwen capsules/granules were listed as the recommended drugs for the "New Coronavirus Pneumonia Diagnosis and Treatment Plan" (trial version 4th, 5th, 6th, 7th, and 8th) jointly issued by the National Health Commission and the State Administration of Traditional Chinese Medicine .
-
Fuhong Hanlius CD73 antibody starts clinical trial
Time of Update: 2021-07-18
This is the third CD73 antibody to enter the clinic after Tianjing Bio and Zhongshan Kangfang .
Previously, Henlius had already declared PD-1 antibody, PD-L1 antibody, EGFR antibody, VEGFR2 antibody, two HER2 antibodies, cMET antibody and LAG-3 antibody in China .
-
Jianfan Bio: Obtained the medical device registration certificate for disposable hemodialysis tubing
Time of Update: 2021-07-18
On March 15th, Jianfan Biological announced that the company has recently received the "Medical Device Registration Certificate" issued by the National Medical Products Administration.
The validity period of the registration certificate: March 10, 2021 Until March 9, 2026, the scope of application: it is used for the function of blood access in hemodialysis treatment .
-
BMS and AVEO reach cooperation on Opdivo and Fotivda in the treatment of kidney cancer
Time of Update: 2021-07-18
A few days ago, AVEO Oncology announced that it has signed a clinical trial cooperation and supply agreement with Bristol Myers Squibb to study the combination of Fotivda (tivozanib) and Bristol Myers Squibb's PD-1 tumor drug Opdivo (nivolumab) for the treatment of advanced immunotherapy.
-
BioXcel's dementia drug BXCL501 receives FDA breakthrough therapy certification
Time of Update: 2021-07-18
A few days ago, BioXcel Therapeutics announced that its research and proprietary oral soluble dexmedetomidine sublingual film preparation BXCL501 has been approved by the FDA as a breakthrough therapy for acute agitation symptoms in patients with Alzheimer’s disease.
-
China Resources Double Crane was honored as one of the “Top 10 Employers with the Most Development Potential in Beijing in 2020 China Employer of the Year”
Time of Update: 2021-07-18
With the theme of "Endogenous Force Reshaping New Life", this event aims to select outstanding employers who can still give employees a sense of security and trust in the face of epidemic challenges and survival crises, and stimulate the symbiosis of organizational effectiveness and talents, and discuss In an uncertain era, how companies can use internal forces to counter the external environment and achieve safe and stable long-term development .
